Resverlogix Corp T.RVX

Alternate Symbol(s): RVXCF

Healthcare Biotechnology

Resverlogix Corp. is a Canada-based late-stage biotechnology company. The Company is engaged in epigenetics, with a focus on developing therapies for the benefit of patients with chronic diseases. Its epigenetic therapies are designed to regulate the expression of disease-causing genes. The Company's clinical program is focused on evaluating its lead candidate apabetalone (RVX-208) for the treatment of cardiovascular disease and associated comorbidities, and post-COVID-19 conditions. RVX-208 is a small molecule that is a selective bromodomain and extra-terminal (BET) inhibitor. BET bromodomain inhibition is an epigenetic mechanism that can regulate disease-causing genes. RVX-208 is a BET inhibitor selective for the second bromodomain (BD2) within the BET proteins. It partners with EVERSANA, to support the commercialization of RVX-208 for cardiovascular disease, post-COVID-19 conditions, and pulmonary arterial hypertension in Canada and the United States.

TSX:RVX - Post by User

Resverlogix Corp

Bullboard Posts

Comment by BearDownAZon Nov 01, 2019 11:59am

128 Views

Post# 30297647

RE:RE:RE:I am new to this stock. Bought this morning @1.40$

"On an other topic, from what is written in earlier posts, i kinda understood we would have an important annoncement by dec. 8th. Am i right?"

Wow, you definitely need to do some DD. Do yourself a favor and look at the slides and more importantly listen to yesterday's webcast. Almost all of the story will be told Nov 16-18 at AHA except for cognition stuff presented at CTAD Dec 5.

https://services.choruscall.ca/links/resverlogixagm20191031.html

https://www.resverlogix.com/upload/media_element/196/eae058d693ff/2019-rvx-agm---final.pdf

Bullboard Posts

Visionstate set to leverage success in the U.S. market